Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q1 2025 Earnings Call Transcript May 5, 2025
Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.50273 EPS, expectations were $-0.44.
Chris Gibson: Hi, everybody. My name is Chris Gibson, Co-Founder and CEO of Recursion, and I’m delighted to welcome you to our Earnings Call this morning. We’re going to go ahead and get started. Perfect. So, of course, important to note that we’re going to be providing...
